About Molbio Diagnostics IPO
Molbio Diagnostics Limited is set to launch its IPO for public subscription on August 10, 2026, and will remain open until August 12, 2026.
The Molbio Diagnostics IPO price band is set at ₹768–₹807 per equity share. The allotment is expected to be finalised on August 13, 2026.
The Molbio Diagnostics IPO is a ₹939.70 crore book-building issue, comprising a fresh issue of 24,80,246 equity shares aggregating to ₹200.00 crore and an offer for sale (OFS) of 91,66,000 equity shares aggregating to ₹739.70 crore, with a face value of ₹1 each.
The company will receive proceeds only from the fresh issue. The OFS amount will go to the selling shareholders. Eligible Employees bidding in the employee reservation portion are offered a discount of ₹76 per share.
Business Overview of Molbio Diagnostics
Molbio Diagnostics Limited, incorporated in October 2000 and headquartered in Verna, Goa, is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing and commercialisation of rapid diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary Truenat platform — a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, which returns accurate test results within an hour.
Molbio offers Molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B and C, and HPV. It also provides radiology, digital pathology and breast health screening solutions through subsidiaries and strategic collaborations.
Key Highlights of Molbio Diagnostics Include:
| Particulars | Details |
|---|---|
| Core Business | Point-of-care molecular diagnostics |
| Flagship Platform | Truenat — portable, battery-operated PCR system |
| Test Menu | 43 diagnostic assays across 30+ diseases |
| Manufacturing | Six facilities across India |
| Geographic Reach | Customers in 90+ countries |
| Total Income (FY26) | ₹1,455.17 crore |
Molbio Diagnostics IPO Date, Price, and Other Details
The following are the IPO details of Molbio Diagnostics out for subscription on August 10, 2026.
| Particulars | Details |
|---|---|
| IPO Size | Book Build issue of ₹939.70 crore |
| Offer Type | Fresh issue of ₹200.00 crore + OFS of ₹739.70 crore |
| Price Band | ₹768 to ₹807 per share |
| Issue Dates | Opens: Aug 10, 2026 · Closes: Aug 12, 2026 |
| Anchor Bidding Date | Aug 7, 2026 |
| Minimum Bid Lot | 1 lot of 18 shares |
| Minimum Investment (Retail) | ₹14,526 (at upper band) |
| Employee Discount | ₹76 per share |
| Allotment Date | Aug 13, 2026 |
| Refund / Credit to Demat | Aug 14, 2026 |
| Listing Date | Aug 17, 2026 |
| Face Value | ₹1 per share |
| Lead Managers (BRLMs) | Kotak Mahindra Capital Co. Ltd.; IIFL Capital Services Ltd.; Jefferies India Pvt. Ltd.; Motilal Oswal Investment Advisors Ltd. |
| Registrar | KFin Technologies Ltd. |
| Listing Exchanges | BSE & NSE |
Molbio Diagnostics IPO Reservation: Who Can Apply?
Indian Residents, HNIs and NRIs (Non-Resident Indians) can apply in Molbio Diagnostics in the following categories:
| Investor Category | Lots | Shares | Amount (at ₹807) |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| sNII (Min) | 14 | 252 | ₹2,03,364 |
| sNII (Max) | 68 | 1,224 | ₹9,87,768 |
| bNII (Min) | 69 | 1,242 | ₹10,02,294 |
| QIB | As applicable | — | — |
Strengths and Risks of Molbio Diagnostics IPO
With every business owning its strengths and risks, even the Molbio Diagnostics IPO has its potential plus points and downsides to be aware of.
Here is a brief business analysis (as per RHP) below:
Strengths
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong in-house R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits and consumables.
- Global presence across more than 90 countries with a strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding the healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
- Total income grew 42% from ₹1,027.94 crore (FY25) to ₹1,455.17 crore (FY26), with PAT rising 18% from ₹138.58 crore to ₹164.14 crore.
Risks
- Around 84.56% of FY26 revenue came from Indian central and state governments and international aid agencies. Changes in public health policy, procurement cycles, or funding could materially affect sales.
- Tuberculosis diagnostic kits contributed roughly 70.20% of FY26 revenue, up from 62.40% in FY24. Even with a positive metric, there is a high single-disease concentration.
- Total borrowings rose from ₹123.16 crore (FY25) to ₹412.64 crore (FY26).
- EBITDA margin of Molbio Diagnostics fell from 24.97% to 22.56% and PAT margin from 13.48% to 11.28%, even as revenue grew 42%.
- The OFS component of ₹739.70 crore accounts for roughly 79% of the issue. Only ₹200.00 crore of fresh issue proceeds comes to the company.
Future Plans/Strategies
- Build out a Dedicated Research and Development Facility and Centre of Excellence with connected office space.
- Expand manufacturing capacity through new plant, machinery and equipment at Goa Unit I, Goa Unit II and the Visakhapatnam Unit.
- Broaden the diagnostics product pipeline beyond TB into a wider infectious and non-communicable disease menu.
- Deepen international presence across the existing 90+ country footprint.
Molbio Diagnostics IPO Objectives — How Will the Funds Be Used?
The Molbio Diagnostics IPO is a combination of a Fresh issue and an OFS. The company will directly receive the proceeds only from the fresh issue of ₹200.00 crore. The OFS proceeds of ₹739.70 crore will go to the selling shareholders.
The key objectives of the offer, as stated in the RHP, include:
| Objective | Amount (₹ crore) |
|---|---|
| Capital expenditure towards setting up infrastructure for an R&D facility, Centre of Excellence and connected office space | ₹125.12 |
| Capital expenditure towards purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and the Visakhapatnam Unit | ₹80.81 |
| General corporate purposes | Shall not exceed 25% of Gross Proceeds |
| Total (identified objects) | ₹205.93 |
Promoter Shareholding of Molbio Diagnostics IPO
The promoters of Molbio Diagnostics Limited are Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan.
| Category | Pre-Issue Holding (%) |
|---|---|
| Promoter and Promoter Group (nil) | 46.65% |
| Public (Other shareholders) | 53.35% |
| Total | 100% |
(Note: Promoter holding is already below 50% pre-issue, which is unusual for a mainboard IPO and reflects earlier institutional funding rounds.)
Financial Performance (₹ in crores) of Molbio Diagnostics IPO
Here's the table outlining the restated financial performance of Molbio Diagnostics from FY 2024 to FY 2025 and up to 31st March, 2026.
(₹ in crores)
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Key Performance Metrics of Molbio Diagnostics
Based on the financials available in the RHP, the following key performance metrics of Molbio Diagnostics Limited can be considered.
| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Return on Equity (ROE) (%) | 15.59 | 16.20 |
| Return on Capital Employed (ROCE) (%) | 17.55 | 20.98 |
| Return on Net Worth (RoNW) (%) | 14.55 | 15.23 |
| Earning per Share (EPS - Diluted) | ₹14.77 | ₹12.87 |
| EBITDA Margin (%) | 22.56 | 24.97 |
| PAT Margin (%) | 11.28 | 13.48 |
| Net Asset Value (NAV) (₹) | 101.51 | 84.51 |
| Number of devices sold | 2,524 | 2,180 |
| Number of test kits sold (in million) | 17.56 | 12.24 |
Registrar of Molbio Diagnostics IPO
The Registrar of Molbio Diagnostics IPO is KFin Technologies Ltd.
Phone: 040-79615565
Email: molbio.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Lead Manager of Molbio Diagnostics IPO
Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited are the book-running lead managers handling the IPO process of Molbio Diagnostics Limited.
